Akari Therapeutics, Plc (AKTX) Financials

AKTX Assets vs Liabilities
DateAssetsLiabilities
Dec. 31, 2025 47.9 million 19.6 million
Sept. 30, 2025 45.4 million 22.7 million
June 30, 2025 50.9 million 25.3 million
March 31, 2025 51.0 million 29.2 million

AKTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2025 -3.0 million 1.2 million
Sept. 30, 2025 -2.1 million 685000
June 30, 2025 -3.3 million 719000
March 31, 2025 -2.2 million 1.0 million

AKTX Net Income

No data available :(

AKTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2025 5.2 million - -
Sept. 30, 2025 2.5 million - -
June 30, 2025 2.7 million - -
March 31, 2025 2.6 million - -

AKTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2025 841601
Sept. 30, 2025 816577
June 30, 2025 393399
March 31, 2025 341176

AKTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2025 - 1.1 million 2.1 million -
Sept. 30, 2025 3 249000 2.0 million -
June 30, 2025 - 667000 2.5 million -
March 31, 2025 - 813000 2.7 million -

AKTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - -
March 31, 2025 25998 1000

AKTX

Price: $13.40

52 week price:
3.02
55.60

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United Kingdom

Volume: 16739

Ebitda: -8.5 million

Market Capitalization: 17.2 million

Links: